RxDoctor Payments DataLook up a doctor →

Lawrence Dubuske, MD

Allergy & Immunology · Washington, DCNPI 1649251778

Payments from drug & device makers

$1,789,252in general payments, 2019–2025

Across 2,095 payments — averaging $854.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$723K
  • Sanofi$402K
  • GSK$372K
  • Regeneron Healthcare Solutions, Inc.$196K
  • Alk-abello, Inc$46K
  • Novartis$13K
  • plus $37K from 21 others

What the payments were for

  • Consulting fees$38,7882%
  • Speaking & faculty fees$1,427,66480%
  • Travel & lodging$281,67316%
  • Food & beverage$40,9032%
  • Education$2060%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,789,252 in reported general payments places this provider in the 90th percentile of 20 allergy & immunology providers in District of Columbia.

See all allergy & immunology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$68,451
Medicare patients
68
Services billed
1,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab14$61,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$56,558
NucalaMepolizumab11$45,059
Spiriva RespimatTiotropium Bromide30$22,520
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,538
Incruse ElliptaUmeclidinium Bromide23$9,177
Arnuity ElliptaFluticasone Furoate23$5,989
DuleraMometasone/Formoterol13$5,702
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,565
Azelastine Hcl73$3,133
Epinephrine17$2,524
Wixela InhubFluticasone Propion/Salmeterol16$2,412
Ipratropium Bromide70$1,977
Famotidine66$1,765
Albuterol Sulfate HfaAlbuterol Sulfate64$1,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta$372,079$116,783118 claims
AstraZenecaBreztri Aerosphere$722,775$12,53820 claims
MerckDulera$15$5,70213 claims
Hikma Pharmaceuticals USAEpinephrine$34$2,52417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 allergy & immunology providers in District of Columbia.

Other allergy & immunology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →